Monoclonal antibody, produced by a single B cell clone, has highly homogeneity that targets a specific antigen epitope. Monoclonal antibody has numerous advantages, including high purity, sensitivity, and specificity. Hybridomas are created through the fusion of B lymphocytes which produce certain specific antibodies, with long-lived myeloma cells. Bioantibody utilizes a high-efficiency fusion technology that is 20 times more effective than conventional fusion methods. Additionally, it employs protein microarray screening technology to identify monoclonal antibodies that exhibit high specificity, affinity, and functional efficacy against specific epitopes.